Nektar Highlights Innovative New Product Development in the Areas of
Oncology, Anti-Infectives, CNS and Pain Therapies
NEW YORK, Nov. 14 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) showcased its two industry-leading Pulmonary and PEGylation technology platforms and the company's innovative proprietary product pipeline at its R&D Day held today at The Palace Hotel in New York.
"Nektar's R&D Day presentation emphasizes our world-class talent and innovative work in the development of breakthrough biopharmaceuticals that leverage our two technology platforms," said Howard W. Robin, President and Chief Executive Officer of Nektar. "Our ground-breaking work in small molecule PEGylation represent significant value for Nektar and promises to result in great improvements to many drugs."
During the event, Nektar scientists and drug development experts highlighted Nektar's pioneering research in the area of small molecule PEGylation and the company's initial market applications of this innovative technology platform in oncology and central nervous system (CNS) therapeutics.
Company Previews NKTR-102 and NKTR-118 Phase 2 Trial Designs
Nektar also previewed its proprietary product clinical development programs, including the Phase 2 clinical trial designs for NKTR-102 (PEG- irinotecan), the company's lead oncolytic candidate under development for the treatment of solid tumors, and NKTR-118 (oral PEG naloxol) for opioid bowel dysfunction.
Nektar Chief Operating Officer and Head of the PEGylation Business
Unit, Hoyoung Huh, M.D., Ph.D. said, "Based on positive Phase 1 results
with our two lead PEG products that leverage our important research in
small molecule PEGy
|SOURCE Nektar Therapeutics|
Copyright©2007 PR Newswire.
All rights reserved